Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
256
Views
11
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma?

Ronghui YangDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; ORCID Iconhttp://orcid.org/0000-0002-1825-8275View further author information
ORCID Icon,
Jin HuangDepartment of Radiotherapy, The First Hospital of China Medical University, Shenyang, China; View further author information
,
Huanxin MaDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; View further author information
,
Shiwen LiDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; View further author information
,
Xin GaoDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; View further author information
,
Yingshu LiuDepartment of Laboratory, Shengjing Hospital of China Medical University, Shenyang, ChinaView further author information
,
Jing ShenDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; View further author information
&
Aijun LiaoDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China; Correspondence[email protected]
View further author information
 show all
Pages 1812-1818 | Received 19 Aug 2018, Accepted 25 Oct 2018, Published online: 10 Jan 2019

References

  • Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16:11–20.
  • Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563–579.
  • Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151–216.
  • Bohlson SS, Fraser DA, Tenner AJ. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol. 2007;44:33–43.
  • Gaboriaud C, Thielens NM, Gregory LA, et al. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 2004;25:368–373.
  • Hu SY, Jia XY, Yang XW, et al. Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunol. 2013;14:42.
  • Son M, Diamond B, Santiago-Schwarz F. Fundamental role of C1q in autoimmunity and inflammation. Immunol Res. 2015;63:101–106.
  • Kohler PF, Muller-Eberhard HJ. Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. J Clin Invest. 1972;51:868–875.
  • Bu X, Zheng Z, Wang C, et al. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract. 2007;203:163–167.
  • Gasque P, Thomas A, Fontaine M, et al. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol. 1996;66:29–40.
  • Lucas SD, Karlsson-Parra A, Nilsson B, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol. 1996;27:1329–1335.
  • Niculescu F, Rus HG, Retegan M, et al. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992;140:1039–1043.
  • Downs-Canner S, Magge D, Ravindranathan R, et al. Complement inhibition: a novel form of immunotherapy for colon cancer. Ann Surg Oncol. 2016;23:655–662.
  • Tokumitsu S, Furuta Y, Kobayashi T, et al. Complete Clq deficiency associated with IgG multiple myeloma. Jpn J Med. 1989;28:216–218.
  • Skoberne M, Somersan S, Almodovar W, et al. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood. 2006;108:947–955.
  • Tripodo C, Porcasi R, Guarnotta C, et al. C1q production by bone marrow stromal cells. Scand J Immunol. 2007;65:308–309.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.